• NeuroOne announced initial OneRF trigeminal nerve ablation results, published online in the peer-reviewed journal Pain Management in October 2026.
• The 15-patient study found immediate pain freedom in most patients; all had favorable outcomes at a mean six-month follow-up.
• The device enabled treatment of multiple nerve distributions without repeated probe repositioning, potentially simplifying treatment.
• The small retrospective study lacked a comparison group; larger studies with longer follow-up are needed to assess lasting relief and comparative effectiveness.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuroone Medical Technologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290800PRIMZONEFULLFEED9855475) on October 29, 2026, and is solely responsible for the information contained therein.